Add Yahoo as a preferred source to see more of our stories on Google. LONDON (Reuters) - Circassia Pharmaceuticals (CIRCI.L), a British company developing allergy therapies, said on Friday it had ...

The UK biotech company is putting its huge failure in allergy treatment behind it with a new deal with AstraZeneca (AZ). But British venture capital leader David Grainger is highly critical of the ...

NIOX Group plc has announced the timetable for its proposed final dividend for the financial year ended 31 December 2025, set at 1.55 pence per share. The company continues to return cash to ...

Steve Harris became the CEO of Circassia Pharmaceuticals plc (LON:CIR) in 2006. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider ...

The most recent earnings announcement Circassia Pharmaceuticals Plc’s (LSE:CIR) released in December 2017 indicated that losses became smaller relative to the prrior year’s level – great news for ...

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the start of a pivotal phase 3 trial of its investigational ToleroMune® cat allergy treatment for cat ...

OXFORD, England, January 19 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has initiated phase II clinical trials of its T-cell ...

With the business potentially at an important milestone, we thought we'd take a closer look at Circassia Group Plc's (LON:CIR) future prospects. Circassia Group Plc, a medical device company, focuses ...

UK biotech Circassia has had two key decisions go in its favour with FDA, as the company continues with its efforts to rebuild its business after a series of disastrous allergy drug trial failures.

- Study Provides Proof-of-Concept for Commercial Formulation and Final Stage of Development Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that the company's ...

OXFORD, England, September 11, 2012--Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the appointment of Dr Brett Haumann as Chief Medical Officer. Dr Haumann ...

LONDON (Reuters) - Circassia Pharmaceuticals, a British company developing allergy therapies, said on Friday it had agreed to buy Sweden's Aerocrine and privately held Prosonix, two companies focused ...